Search

Your search keyword '"Diagnostic reagents industry -- Securities"' showing total 384 results
Start Over Descriptor "Diagnostic reagents industry -- Securities"
384 results on '"Diagnostic reagents industry -- Securities"'

1. Revvity Board Declares Quarterly Dividend

Subjects
Revvity Inc. -- Securities, Diagnostic reagents industry -- Securities, Dividends, Company dividends, Company securities, Business, Business, international
Abstract

WALTHAM, Mass. -- The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on [...]

Published
2024

2. Moody's Ratings affirms Revvity's Baa3 senior unsecured ratings; outlook stable

Subjects
Revvity Inc. -- Securities, Moody's Investors Service Inc. -- Securities, Diagnostic reagents industry -- Securities, Company securities, General interest, News, opinion and commentary
Abstract

New York City: Moody's Investors Service has issued the following news release: Moody's Ratings (Moody's) affirmed the Baa3 senior unsecured ratings of Revvity, Inc. ('Revvity'). The outlook remains stable. The [...]

Published
2024

3. Investing in Undervalued Mid-Cap Stocks Amid Growing Rate Uncertainty

Subjects
Quidel Corp. -- Securities, Euronet Worldwide Inc. -- Securities, Financial analysts, Stocks, Data processing services -- Securities, Diagnostic reagents industry -- Securities, Company securities, General interest, News, opinion and commentary
Abstract

* Mid-cap stocks offer a balance of growth potential and stability between small and large caps. * Euronet Worldwide and Quidel Corporation are strong mid-cap companies with different growth paths. [...]

Published
2024

4. Quidel Buying Ortho Clinical Diagnostics for $6 Billion: HEALTHCARE: Deal Highlights Red-Hot Diagnostics Sector

Author

Lurie, George

Subjects
Quidel Corp. -- Securities, Securities offerings, Diagnostic reagents industry -- Securities, Company securities, Business, Business, regional
Abstract

San Diego-based Quidel (NASDAQ: QDEL) has agreed to acquire Ortho Clinical Diagnostics Holdings (NAS-DAQ: OCDX) for $6 billion. Under the terms of the agreement, announced Dec. 23, Quidel will buy [...]

Published
2022

5. Quidel to acquire Raritan's Ortho Clinical Diagnostics for $6

Subjects
Quidel Corp. -- Securities, Diagnostic reagents industry -- Securities, Company securities, Business, regional
Abstract

Byline: Jessica Perry Raritan's Ortho Clinical Diagnostics Holdings plc and Quidel Corp., based in San Diego, on Dec. 23 announced entering a definitive agreement that will see Quidel acquire Ortho [...]

Published
2021

7. In vitro test maker Ortho Clinical Diagnostics files $1.5B Nasdaq IPO

Author

Hale, Conor

Subjects
Renaissance Capital Finance -- Securities, Ortho-Clinical Diagnostics Inc. -- Securities, Securities, Company securities, Diagnostic equipment (Medical), Stock offerings, Investment banks, Diagnostic reagents industry -- Securities, COVID-19
Published
2021

8. Drug Industry

Subjects
Genzyme Corp. -- Securities, Gilead Sciences Inc. -- Securities, GlaxoSmithKline AB -- Securities, Valeant Pharmaceuticals International -- Securities, IDEC Pharmaceuticals Corp. -- Securities, Pharmacia Corp. -- Securities, Perrigo Co. -- Securities, Pfizer Inc. -- Securities, Pharmaceutical Product Development Inc. -- Securities, Protein Design Labs Inc. -- Securities, Quintiles Transnational Corp. -- Securities, Schering-Plough Corp. -- Securities, Sicor Inc. -- Securities, Tularik Inc. -- Securities, Watson Pharmaceuticals Inc. -- Securities, Wyeth Co. -- Securities, Nektar Therapeutics -- Securities, Neurocrine Biosciences Inc. -- Securities, Novartis AG -- Securities, Novo Nordisk A/S -- Securities, PAREXEL International Corp. -- Securities, Abgenix Inc. -- Securities, Albany Molecular Research Inc. -- Securities, Andrx Group -- Securities, Aventis Behring L.L.C. -- Securities, Barr Laboratories Inc. -- Securities, Biovail Corporation International -- Securities, Bristol-Myers Squibb Co. -- Securities, Celgene Corp. -- Securities, Cephalon Inc. -- Securities, Chiron Corp. -- Securities, Covance Inc. -- Securities, Enzon Inc. -- Securities, Forest Laboratories Inc. -- Securities, ImClone Systems Inc. -- Securities, IVAX Corp. -- Securities, King Pharmaceuticals Inc. -- Securities, Lilly and Associates International -- Securities, Medarex Inc. -- Securities, Medicis Pharmaceutical Corp. -- Securities, MedImmune L.L.C. -- Securities, Merck & Company Inc. -- Securities, Mylan Inc. -- Securities, Biotechnology industry -- Securities, Business consultants -- Securities, Pharmaceutical industry -- Securities, High technology industry -- Securities, Biological products industry -- Securities, Diagnostic reagents industry -- Securities, Shipping industry -- Securities, Vaccines industry -- Securities, Company securities, Business, Business, general
Abstract

Financial analysis of Drug industry securities is given. Securities performance is outlined through graphs, charts and forecasting data.

Published
2003

9. Medical supplies industry

Author

Rho, George, Markey, Keith A., Van Liew, Nils C., Nugent, Kenneth A., Beyrouty, Joseph A., Chow, Nancy, Cathers, Dylan D., Virgile, Lucien, Hudson, Alex, and Costanza, Andre J.

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Securities, Affymax Inc. -- Securities, Allergan Inc. -- Securities, Alpharma Inc. -- Securities, AmerisourceBergen Corp. -- Securities, Apogent Technologies Inc. -- Securities, Arrow International Inc. -- Securities, ArthroCare Corp. -- Securities, C.R. Bard Inc. (Murray Hill, New Jersey) -- Securities, Bausch & Lomb Inc. -- Securities, Baxter International Inc. (Deerfield, Illinois) -- Securities, Beckman Coulter Inc. -- Securities, Becton Dickinson and Co. -- Securities, Bio-Rad Laboratories Inc. -- Securities, Biomet Inc. -- Securities, Boston Scientific Corp. -- Securities, Cardinal Health Inc. -- Securities, Charles River Laboratories International Inc. -- Securities, CONMED Corp. -- Securities, Cooper Companies Inc. -- Securities, CryoLife Inc. -- Securities, Cytyc Corp. -- Securities, Datascope Corp. -- Securities, DENTSPLY International Inc. -- Securities, Diagnostic Products Corp. -- Securities, Digene Corp. -- Securities, Fisher Scientific International Inc. -- Securities, Guidant Corp. -- Securities, Haemonetics Corp. -- Securities, IDEXX Laboratories Inc. -- Securities, Illumina Inc. -- Securities, INAMED Corp. -- Securities, Invacare Corp. -- Securities, Johnson & Johnson -- Securities, McKesson Corp. -- Securities, Medtronic Inc. -- Securities, Mentor Corp. -- Securities, Microvision Inc. -- Securities, Molecular Devices Corp. -- Securities, Ocular Sciences Inc. -- Securities, Osteotech Inc. -- Securities, Owens & Minor Inc. -- Securities, Patterson Dental Co. -- Securities, Priority Healthcare Corp. -- Securities, ResMed Inc. -- Securities, Respironics Inc. -- Securities, St. Jude Medical Inc. -- Securities, Henry Schein Inc. -- Securities, Sola International Inc. -- Securities, STERIS Corp. -- Securities, Stryker Corp. -- Securities, Thoratec Corp. -- Securities, VISX Inc. -- Securities, Varian Medical Systems Inc. -- Securities, West Pharmaceutical Services Inc. -- Securities, Zimmer Holdings Inc. -- Securities, Pharmaceutical industry -- Securities, Medical equipment and supplies industry -- Securities, Surgical equipment and supplies industry -- Securities, Eyewear industry -- Securities, Instrument industry -- Securities, Health products industry -- Securities, Wholesale industry -- Securities, Health care industry -- Securities, Dental equipment and supplies industry -- Securities, Diagnostic reagents industry -- Securities, Scientific equipment and supplies industry -- Securities, Biological products industry -- Securities, Optical instruments industry -- Securities, Business, Business, general
Abstract

Earnings for the medical supplies industry have been good during the year 2002, especially the dental supply sector. The market for medical supplies, especially stents, is being transformed for the better, also. There are many good stocks for the investor to select in this industry.

Published
2002

10. Drug industry

Author

Rho, George, Clark, Charles, Rosner, Adam, Ferro, Mario, Schlein, Milton, Feenan, Gerard, Butler, Jeremy J., Jones, Stephen, Chow, Nancy, Ferrera, J. Susan, Markey, Keith A., Romaine, Sigourney B., and Harris, Frederick L., III

Subjects
Abgenix Inc. -- Securities, Albany Molecular Research Inc. -- Securities, Andrx Group -- Securities, Aventis S.A. -- Securities, Barr Laboratories Inc. -- Securities, Biovail Corp. -- Securities, Bristol-Myers Squibb Co. -- Securities, Cephalon Inc. -- Securities, Chiron Corp. -- Securities, Covance Inc. -- Securities, Elan Corporation PLC -- Securities, Forest Laboratories Inc. -- Securities, Genzyme Corp. -- Securities, Gilead Sciences Inc. -- Securities, GlaxoSmithKline Inc. (Research Triangle Park, North Carolina) -- Securities, Valeant Pharmaceuticals International -- Securities, IDEC Pharmaceuticals Corp. -- Securities, ImClone Systems Inc. -- Securities, Inhale Therapeutic Systems Inc. -- Securities, IVAX Corp. -- Securities, King Pharmaceuticals Inc. -- Securities, Eli Lilly and Co. -- Securities, Medarex Inc. -- Securities, Medicis Pharmaceutical Corp. -- Securities, MedImmune L.L.C. -- Securities, Merck & Company Inc. -- Securities, Mylan Inc. -- Securities, Neurocrine Biosciences Inc. -- Securities, Novartis AG -- Securities, Novo Nordisk A/S -- Securities, PAREXEL International Corp. -- Securities, Perrigo Co. -- Securities, Pfizer Inc. -- Securities, Pharmaceutical Product Development Inc. -- Securities, Pharmacia Corp. -- Securities, Protein Design Labs Inc. -- Securities, Quintiles Transnational Corp. -- Securities, Schering-Plough Corp. -- Securities, Sepracor Inc. -- Securities, Sicor Inc. -- Securities, Tularik Inc. -- Securities, Watson Pharmaceuticals Inc. -- Securities, Wyeth Co. -- Securities, Pharmaceutical industry -- Securities, Biological products industry -- Securities, Biotechnology industry -- Securities, Diagnostic reagents industry -- Securities, Vaccines industry -- Securities, Business, Business, general
Abstract

The performance of pharmaceutical industry stocks has been poor in the year 2002 due to the operating environment. Few companies are prepared for the costly product development process the industry requires, but profit growth should improve in the future. Few of these stocks are timely for the year 2002.

Published
2002

11. Back to Basics

Author

Nelson, Wayne F. and McLellan, Ellen S.

Subjects
Allied Capital Corp. -- Securities, IGEN International Inc. -- Securities, Lockheed Martin Corp. -- Securities, Martek Biosciences Corp. -- Securities, MedImmune L.L.C. -- Securities, Aircraft industry -- Securities, Corporations -- Securities, Diagnostic reagents industry -- Securities, Investment advisers -- Beliefs, opinions and attitudes, Pharmaceutical industry -- Securities, Stocks -- Evaluation, Venture capital companies -- Securities, Company securities, Travel, recreation and leisure
Abstract

The stock prospects of ten healthy local companies, including Allied Capital, IGEN International, Lockheed Martin, Martek Biosciences and six others. Investment advisors recommend focusing on company leadership.

Published
2002

12. Drug industry

Author

Rho, George, Clark, Charles, Rosner, Adam, Schlein, Milton, Feenen, Gerard, Butler, Jeremy J., Jones, Stephen, Gallen, David, Chow, Nancy, Ferro, Mario, Markey, Keith A., Ferrara, J. Susan, Romaine, Sigourney B., and Harris, Frederick L., III

Subjects
Abgenix Inc. -- Securities, Albany Molecular Research Inc. -- Securities, Andrx Group -- Securities, Barr Laboratories Inc. -- Securities, Biovail Corp. -- Securities, Bristol-Myers Squibb Co. -- Securities, Cephalon Inc. -- Securities, Chiron Corp. -- Securities, Covance Inc. -- Securities, Cygnus Inc. -- Securities, Elan Corporation PLC -- Securities, Enzon Inc. -- Securities, Forest Laboratories Inc. -- Securities, Genzyme Corp. -- Securities, Gilead Sciences Inc. -- Securities, GlaxoSmithKline PLC -- Securities, Valeant Pharmaceuticals International -- Securities, IDEC Pharmaceuticals Corp. -- Securities, ImClone Systems Inc. -- Securities, Inhale Therapeutic Systems Inc. -- Securities, IVAX Corp. -- Securities, King Pharmaceuticals Inc. -- Securities, Eli Lilly and Co. -- Securities, Medarex Inc. -- Securities, Medicia Pharmaceutical Corp. -- Securities, MedImmune L.L.C. -- Securities, Merck & Company Inc. -- Securities, Mylan Inc. -- Securities, Neurocrine Biosciences Inc. -- Securities, Novartis AG -- Securities, PAREXEL International Corp. -- Securities, Perrigo Co. -- Securities, Pfizer Inc. -- Securities, Pharmaceutical Product Development Inc. -- Securities, Pharmacia Corp. -- Securities, Protein Design Labs Inc. -- Securities, Quintiles Transnational Corp. -- Securities, Schering-Plough Corp. -- Securities, Sepracor Inc. -- Securities, Sicor Inc. -- Securities, Tularik Inc. -- Securities, Watson Pharmaceuticals Inc. -- Securities, Wyeth Co. -- Securities, Pharmaceutical industry -- Securities, Biological products industry -- Securities, Biotechnology industry -- Securities, Diagnostic reagents industry -- Securities, Vaccines industry -- Securities, Business, Business, general
Abstract

Drug industry stocks ended lower in the 4th qtr of 2002 as industry fundamentals declined. Industry consolidation may continue in the future, and the aging populations of Europe, Japan, and the US should increase demand for pharmaceuticals. Investors need to be selective with these stocks.

Published
2002

13. Drug industry

Author

Rho, George, Clark, Charles, Harris, Frederick L. III, Rosner, Adam, Schlein, Milton, Feenan, Gerard, Butler, Jeremy J., Jones, Stephen, Gallen, David, Chow, Nancy, Ferro, Mario, Markey, Keith A., Ferrara, J. Susan, and Romaine, Sigourney B.

Subjects
Abgenix Inc. -- Securities, Albany Molecular Research Inc. -- Securities, Wyeth -- Securities, Andrx Group -- Securities, Barr Laboratories Inc. -- Securities, Biovail Corp. -- Securities, Bristol-Myers Squibb Co. -- Securities, Cephalon Inc. -- Securities, Chiron Corp. -- Securities, Covance Inc. -- Securities, Cygnus Inc. -- Securities, Elan Corporation PLC -- Securities, Enzon Inc. -- Securities, Forest Laboratories Inc. -- Securities, Genzyme Corp. -- Securities, Gilead Sciences Inc. -- Securities, GlaxoSmithKline PLC -- Securities, Valeant Pharmaceuticals International -- Securities, IDEC Pharmaceuticals Corp. -- Securities, ImClone Systems Inc. -- Securities, Inhale Therapeutic Systems Inc. -- Securities, IVAX Corp. -- Securities, King Pharmaceuticals Inc. -- Securities, Eli Lilly and Co. -- Securities, Medarex Inc. -- Securities, Medicis Pharmaceutical Corp. -- Securities, MedImmune L.L.C. -- Securities, Merck & Company Inc. -- Securities, Mylan Inc. -- Securities, Neurocrine Biosciences Inc. -- Securities, Novartis AG -- Securities, PAREXEL International Corp. -- Securities, Perrigo Co. -- Securities, Pfizer Inc. -- Securities, Pharmaceutical Product Development Inc. -- Securities, Protein Design Labs Inc. -- Securities, Quintiles Transnational Corp. -- Securities, Schering-Plough Corp. -- Securities, Sepracor Inc. -- Securities, Sicor Inc. -- Securities, Tularik Inc. -- Securities, Watson Pharmaceuticals Inc. -- Securities, Pharmaceutical industry -- Securities, Biological products industry -- Securities, Biotechnology industry -- Securities, Diagnostic reagents industry -- Securities, Vaccines industry -- Securities, Business, Business, general
Abstract

The drug industry is expected to have a good year in 2002, although the year 2001 was not a good one for the industry. The year 2002 will also be a transitional one for the industry, with the industrial nation's aging population needing more medications. These stocks are timely for investors in the year 2002.

Published
2002

14. Drug industry

Author

Rho, George, Clark, Charles, Harris, Frederick L. III, Rosner, Adam, Schlein, Milton, Feenan, Gerard, Butler, Jeremy J., Jones, Stephen E., Gallen, David, Chow, Nancy, Ferro, Mario, Markey, Keith A., Ferrara, J. Susan, and Romaine, Sigourney B.

Subjects
Abgenix Inc. -- Securities, Wyeth -- Securities, Andrx Corp. -- Securities, Barr Laboratories Inc. -- Securities, Biovail Corp. -- Securities, Bristol-Myers Squibb Co. -- Securities, Cephalon Inc. -- Securities, Chiron Corp. -- Securities, Covance Inc. -- Securities, Cygnus Inc. -- Securities, Elan Corporation PLC -- Securities, Forest Laboratories Inc. -- Securities, Genzyme Corp. -- Securities, Gilead Sciences Inc. -- Securities, GlaxoSmithKline Inc. (Research Triangle Park, North Carolina) -- Securities, Valeant Pharmaceuticals International -- Securities, IDEC Pharmaceuticals Corp. -- Securities, ImClone Systems Inc. -- Securities, Inhale Therapeutic Systems Inc. -- Securities, IVAX Corp. -- Securities, King Pharmaceuticals Inc. -- Securities, Eli Lilly and Co. -- Securities, Medarex Inc. -- Securities, Medicis Pharmaceutical Corp. -- Securities, MedImmune L.L.C. -- Securities, Merck & Company Inc. -- Securities, Mylan Inc. -- Securities, Novartis AG -- Securities, PAREXEL International Corp. -- Securities, Perrigo Co. -- Securities, Pfizer Inc. -- Securities, Pharmaceutical Product Development Inc. -- Securities, Pharmacia Corp. -- Securities, Protein Design Labs Inc. -- Securities, Quintiles Transnational Corp. -- Securities, Schering-Plough Corp. -- Securities, Sepracor Inc. -- Securities, Sicor Inc. -- Securities, Watson Pharmaceuticals Inc. -- Securities, Pharmaceutical industry -- Securities, Biological products industry -- Securities, Biotechnology industry -- Securities, Health products industry -- Securities, Wholesale industry -- Securities, Diagnostic reagents industry -- Securities, Vaccines industry -- Securities, Business, Business, general
Abstract

The pharmaceuticals industry has done well in the year 2001 in spite of the slower US economy and the Sep 11, 2001 terrorist attacks. However, the lapse of patents presents a challenge to many drug companies. These stocks are timely for 2001 and the next three to five years.

Published
2001

15. Quidel Announces Private Exchange Transactions

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, Securities offerings, Company securities, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Quidel Corporation has issued the following press release: Quidel Corporation (NASDAQ: QDEL) ('Quidel'), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced [...]

Published
2019

16. Quidel Announces Private Exchange Transactions

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, Securities offerings, Company securities, Business, Business, international
Abstract

SAN DIEGO -- Quidel Corporation (NASDAQ: QDEL) ('Quidel'), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has entered into separate, [...]

Published
2019

17. Moody's announces completion of a periodic review of ratings of Lantheus Medical Imaging, Inc

Subjects
Moody's Investors Service Inc. -- Securities, Lantheus Medical Imaging Inc. -- Securities, Diagnostic reagents industry -- Securities, Medical imaging equipment -- Evaluation, Company securities, General interest, News, opinion and commentary
Abstract

New York City: Moody's Investors Service has issued the following press release:Moody's Investors Service ('Moody's') has completed a periodic review of the ratings of Lantheus Medical Imaging, Inc and other [...]

Published
2019

18. FORM 8-K: QUIDEL CORP|DE Files Current Report Updated on 01-06-18

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, State laws, Company securities, General interest, News, opinion and commentary
Abstract

Washington: QUIDEL CORP /DE , has filed FORM 8-K (Current Report) with Securities and Exchange Commission on June 01, 2018 Item 3.02 UREGISTERED SALES OF EQUITY SECURITIES On May 31, [...]

Published
2018

19. Quidel Announces Private Exchange Transactions (Updated on 31 May 2018)

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, Company securities, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Quidel Corporation has issued the following press release: Quidel Corporation (NASDAQ: QDEL) ('Quidel'), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced [...]

Published
2018

20. Quidel Announces Private Exchange Transactions

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, Company securities, Business, Business, international
Abstract

SAN DIEGO -- Quidel Corporation (NASDAQ: QDEL) ('Quidel'), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has entered into separate, privately [...]

Published
2018

21. Quidel Announces Private Exchange Transactions

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, Company securities, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Quidel Corporation has issued the following press release: Quidel Corporation (NASDAQ: QDEL) ('Quidel'), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced [...]

Published
2018

22. Quidel Announces Private Exchange Transactions

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, Company securities, Business, Business, international
Abstract

SAN DIEGO -- Quidel Corporation (NASDAQ: QDEL) ('Quidel') ,a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has entered into separate, privately [...]

Published
2018

23. Playing to win: Medical devices is a higher stakes game with a higher payoff. Winners must be broad in scope and technology savvy

Author

O'Connor, Robert

Subjects
Medtronic PLC -- Securities, ALZA Corp. -- Securities, CardioDynamics International Corp. -- Securities, Johnson & Johnson Medical Inc. -- Securities, IGEN International Inc. -- Securities, Securities, Company securities, Diagnostic equipment (Medical), Diagnostic reagents industry -- Securities, Drugs, Medical equipment industry -- Securities, Diagnostic reagents, Medical equipment, Pharmaceutical industry -- Securities, Cardiovascular equipment, Medical test kit industry -- Securities, Medical equipment and supplies industry -- Securities, Physiological apparatus
Abstract

The medical device and technology market offers promise for investors. The aging of the U.S. population, combined with longer life expectancies, is feeding growing demand for products and providing a [...]

Published
2002

24. Quidel Announces Private Exchange Transactions

Subjects
Quidel Corp. -- Securities, Stock offerings, Diagnostic reagents industry -- Securities, Securities offerings, Company securities, Business, Business, international
Abstract

HONG KONG, June 4 -- Quidel Corporation issued the following news release: Quidel Corporation (NASDAQ: QDEL) ('Quidel'), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic [...]

Published
2019

27. Neopharm Inc

Subjects
NeoPharm Inc. -- Securities, Diagnostic reagents industry -- Securities
Published
2000

28. Imclone Systems Inc

Subjects
ImClone Systems Inc. -- Securities, Diagnostic reagents industry -- Securities
Published
2000

29. Profile of Julian Baines, Chief Executive Officer of EKF Diagnostics

Subjects
Alere Inc. -- Securities, Chief executive officers, Diagnostic reagents industry -- Securities, Company securities, General interest, News, opinion and commentary
Abstract

Dublin: Following is the Profile of Julian Baines, Chief Executive Officer of EKF Diagnostics: Julian was Group CEO of BBI where he undertook a management buyout in 2000, a flotation [...]

Published
2018

30. Profile of Julian Baines, Chief Executive Officer of EKF Diagnostics

Subjects
Alere Inc. -- Securities, Chief executive officers, Diagnostic reagents industry -- Securities, Company securities, General interest, News, opinion and commentary
Abstract

Dublin: Following is the Profile of Julian Baines, Chief Executive Officer of EKF Diagnostics: Julian was Group CEO of BBI where he undertook a management buyout in 2000, a flotation [...]

Published
2018

31. Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock

Subjects
United States. Securities and Exchange Commission, Alere Inc. -- Securities, Abbott Laboratories (Abbott Park, Illinois) -- Securities, Diagnostic reagents industry -- Securities, Capital stock, Preferred stocks, Pharmaceutical industry -- Securities, Dividends, Company securities, Company dividends, Business, News, opinion and commentary
Abstract

WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B [...]

Published
2017

32. Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock

Subjects
Alere Inc. -- Securities, Dividends, Diagnostic reagents industry -- Securities, Preferred stocks, Company securities, Company dividends, General interest, News, opinion and commentary
Abstract

WALTHAM: Alere Inc has issued the following press release: Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its [...]

Published
2017

33. Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock

Subjects
Alere Inc. -- Securities, Dividends, Diagnostic reagents industry -- Securities, Preferred stocks, Company securities, Company dividends, Business, News, opinion and commentary
Abstract

WALTHAM, Mass., June 23, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B [...]

Published
2017

34. Profile of George Migausky Executive Vice President and Chief Financial Officer of Dimension Therapeutics

Subjects
IGEN International Inc. -- Securities, Diagnostic reagents industry -- Securities, Initial public offerings, Chief financial officers, Company public offering, Company securities, General interest, News, opinion and commentary
Abstract

Woburn, MA: Following is the Profile of George Migausky Executive Vice President and Chief Financial Officer of Dimension Therapeutics: George Migausky has served as Executive Vice President and Chief Financial [...]

Published
2017

35. Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock

Subjects
Alere Inc. -- Securities, Dividends, Diagnostic reagents industry -- Securities, Preferred stocks, Company securities, Company dividends, Business, News, opinion and commentary
Abstract

WALTHAM, Mass., March 20, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B [...]

Published
2017

36. S&P Picks and Pans: Citigroup, Wells Fargo, ImClone, Royal Bank of Scotland, AMB Property; Analysts' opinions on stocks in the news Monday

Subjects
Diagnostic reagents industry -- Securities, Stocks -- Prices and rates, Financial services industry -- Securities, Banking industry -- Securities, Company securities, Company pricing policy, Financial services industry, Banking industry, Citigroup Inc. -- Securities, Wells Fargo & Co. -- Securities, ImClone Systems Inc. -- Securities
Published
2008

37. Why All the ImClone Interest? Its Pipeline; Big Pharma, hungry to fill thinning sales kits with better-protected oncology drugs, is circling Carl Icahn's hot property

Author

Arnst, Catherine

Subjects
Erbitux (Medication) -- Product information, Diagnostic reagents industry -- Product information, Diagnostic reagents industry -- Securities, Stocks -- Prices and rates, Company securities, Company pricing policy, ImClone Systems Inc. -- Product information, ImClone Systems Inc. -- Securities
Published
2008

39. IMCLONE'S NEW BIDDER

Author

Maurer, Harry and Linblad, Cristina

Subjects
Company securities, ImClone Systems Inc. -- Securities, Diagnostic reagents industry -- Securities
Published
2008

41. ICAHN RESISTS..

Author

Maurer, Harry and Linblad, Cristina

Subjects
Company acquisition/merger, Company securities, Bristol-Myers Squibb Co. -- Mergers, acquisitions and divestments, ImClone Systems Inc. -- Officials and employees, ImClone Systems Inc. -- Mergers, acquisitions and divestments, ImClone Systems Inc. -- Securities, Pharmaceutical industry -- Mergers, acquisitions and divestments, Diagnostic reagents industry -- Officials and employees, Diagnostic reagents industry -- Mergers, acquisitions and divestments, Diagnostic reagents industry -- Securities
Published
2008

42. Movers: Exxon Mobil, WaMu, ImClone Systems, Marathon Oil, Disney, MasterCard; Stocks in the news on Thursday

Subjects
Petroleum industry -- Securities, Diagnostic reagents industry -- Securities, Credit and debit card industry -- Securities, Transportation equipment industry -- Securities, Automobile industry -- Securities, Company securities, Automobile Industry, Motors Liquidation Co. -- Securities, Ford Motor Co. -- Securities, Chrysler L.L.C. -- Securities, Standard & Poor's Rating Services -- Securities, Exxon Mobil Corp. -- Securities, ImClone Systems Inc. -- Securities, MasterCard International Inc. -- Securities
Published
2008

43. S&P Picks and Pans: Wachovia, ImClone Systems, Weyerhaeuser, Red Hat, CBRL Group; Analysts' opinions on stocks in the news Monday

Subjects
Banking industry -- Forecasts and trends, Banking industry -- Securities, Diagnostic reagents industry -- Securities, Diagnostic reagents industry -- Forecasts and trends, Paper industry -- Securities, Paper industry -- Forecasts and trends, Company securities, Market trend/market analysis, Banking industry, Wachovia Corp. (Winston-Salem, North Carolina) -- Securities, Wachovia Corp. (Winston-Salem, North Carolina) -- Forecasts and trends, ImClone Systems Inc. -- Securities, ImClone Systems Inc. -- Forecasts and trends, Weyerhaeuser Co. -- Securities, Weyerhaeuser Co. -- Forecasts and trends
Published
2008

44. Analyst Actions: ImClone Systems, Blockbuster, Build-A-Bear

Subjects
Diagnostic reagents industry -- Securities, Diagnostic reagents industry -- Forecasts and trends, Toy industry -- Securities, Toy industry -- Forecasts and trends, Video stores -- Securities, Video stores -- Forecasts and trends, Market trend/market analysis, Company securities, ImClone Systems Inc. -- Securities, ImClone Systems Inc. -- Forecasts and trends, Blockbuster Inc. -- Securities, Blockbuster Inc. -- Forecasts and trends, Build-A-Bear Workshop -- Securities, Build-A-Bear Workshop -- Forecasts and trends
Published
2008

45. Analyst Actions: Intuit, United Natural Foods, ImClone, Cbeyond; Opinions on various stocks Friday

Subjects
Canned foods industry -- Securities, Canned foods industry -- Forecasts and trends, Diagnostic reagents industry -- Securities, Diagnostic reagents industry -- Forecasts and trends, Telecommunications services industry -- Securities, Telecommunications services industry -- Forecasts and trends, Communications industry -- Securities, Communications industry -- Forecasts and trends, Telecommunications services industry, Company securities, Market trend/market analysis, United Natural Foods Inc. -- Securities, United Natural Foods Inc. -- Forecasts and trends, ImClone Systems Inc. -- Securities, ImClone Systems Inc. -- Forecasts and trends, Cbeyond Communications -- Securities, Cbeyond Communications -- Forecasts and trends
Published
2008

46. Lantheus Holdings, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 3, 2018)

Subjects
Lantheus Medical Imaging Inc. -- Securities, United States. Securities and Exchange Commission -- Powers and duties, Powers and duties, Securities, Company securities, Diagnostic reagents industry -- Securities, Corporate directors, Editors
Abstract

2018 DEC 21 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. [...]

Published
2018

47. S&P PIcks and Pans: Bristol-Myers, Countrywide, Take-Two; Analyst opinions on stocks making headlines Tuesday

Subjects
Pharmaceutical industry -- Securities, Pharmaceutical industry -- Forecasts and trends, Diagnostic reagents industry -- Securities, Diagnostic reagents industry -- Forecasts and trends, Mortgage banks -- Securities, Mortgage banks -- Forecasts and trends, Computer software industry -- Securities, Computer software industry -- Forecasts and trends, Company securities, Market trend/market analysis, ImClone Systems Inc. -- Securities, ImClone Systems Inc. -- Forecasts and trends, Bristol-Myers Squibb Co. -- Forecasts and trends, Bristol-Myers Squibb Co. -- Securities, Bank of America Home Loans -- Securities, Bank of America Home Loans -- Forecasts and trends, Take-Two Interactive Software Inc. -- Securities, Take-Two Interactive Software Inc. -- Forecasts and trends
Published
2007

48. Movers: Countrywide Financial, ImClone Systems, McDonald's; Tuesday's stocks in the news

Subjects
Pharmaceutical industry -- Securities, Pharmaceutical industry -- Forecasts and trends, Diagnostic reagents industry -- Securities, Diagnostic reagents industry -- Forecasts and trends, Mortgage banks -- Securities, Mortgage banks -- Forecasts and trends, Company securities, Market trend/market analysis, ImClone Systems Inc. -- Securities, ImClone Systems Inc. -- Forecasts and trends, Bank of America Home Loans -- Securities, Bank of America Home Loans -- Forecasts and trends, King Pharmaceuticals Inc. -- Securities, King Pharmaceuticals Inc. -- Forecasts and trends
Published
2007

50. Street Cheers ImClone, but Analysts Remain Wary; The stock gained amid word of a fresh tussle between the drug outfit's board and Carl Icahn, who refused to support a $36 a share buyout bid

Subjects
Diagnostic reagents industry -- Securities, Diagnostic reagents industry -- Company forecasts, Diagnostic reagents industry -- Management, Company securities, Company business forecast/projection, Company business management, ImClone Systems Inc. -- Securities, ImClone Systems Inc. -- Company forecasts, ImClone Systems Inc. -- Management
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results